Biotech & Longevity: 29 Jun – 5 Jul
No boards ran in this window, so there is no arc to read.
—
pressure at the week’s end, 0–100
—
move across the week
7
editions published
560
sources read behind them
No written analysis for this week
Everything on this page is measured from the week’s own boards and editions. The written read is added when the engine runs its report pass; a week without one still has its record.
The week’s editions · 7
The third company to crack an "undruggable" cancer target just beat the two that got there first
China clears the first CAR-T for a solid tumor — the wall cancer therapy has hit for 15 years
The gene-editing drug that doesn't cut the gene — a muscle disease is the first test
The FDA delays a rare-epilepsy drug three months — and analysts blame last year's staff cuts
The FDA seats a panel on wellness peptides — and most of the panelists sell them
A big fish-oil trial proves the pills reach the brain — and do nothing for it
An LSD pill posts the best depression data the field has seen — and the hardest result to read
The same week, another beat